Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3PSUF)

• Drug Name: MK-3102 Drug Info
• Synonyms: Omarigliptin

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 46209133
  ChEBI ID: CHEBI:134735
  CAS Number: CAS 1226781-44-7
  TTD Drug ID: DM3PSUF
  VARIDT Drug ID: DR00765

Molecule-Related Drug Atlas

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[3]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[4]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[5]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[6]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[7]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[8]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[9]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[10]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[11]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Modulator	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8402).
• [2] Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.
• [3] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [4] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [5] Clinical pipeline report, company report or official report of Takeda (2009).
• [6] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [7] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [10] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [11] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [12] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.